EXPLORE!

GBS Listed As Very Rare Side Effect of AstraZeneca COVID-19 Vaccine

  623 Views

#Hospital Medicine  #Infectious Diseases  #Neurology  #Pathology and Lab Medicine  #Pharmacist  #Public Health  #Pulmonary Medicine 

eMediNexus    10 September 2021

The European Medicines Agency has listed Guillain-Barre syndrome (GBS), a neurological disorder known to cause temporary paralysis, as a very rare side effect of AstraZeneca COVID-19 vaccine.

With 833 cases of GBS reported worldwide as of July 31, from around 592 million doses of the AstraZeneca "Vaxzevria" vaccine administered, the EMA stated that a causal relationship was "considered at least a reasonable possibility".

The EMA said that GBS should be added to the product information as a side effect of the vaccine, and stated that the syndrome was a very rare side effect, noted in less than one in 10,000 individuals… (NDTV – AFP, September 9, 2021)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.